bioMerieux (EYWN) Financial Statements
bioMerieux Financial Overview
bioMerieux's market cap is currently $10.69B. The company's EPS TTM is $3.93; its P/E ratio is 23.03; and it has a dividend yield of 1.09%. bioMerieux is estimated to report earnings on March 4, 2027, and the estimated EPS forecast is $2.45. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 4.07B | $ 3.98B | $ 3.67B | $ 3.59B | $ 3.38B |
| Gross Profit | $ 2.14B | $ 2.22B | $ 2.06B | $ 1.96B | $ 1.97B |
| Operating Income | $ 561.20M | $ 588.80M | $ 439.10M | $ 559.80M | $ 768.00M |
| EBITDA | $ 999.60M | $ 897.50M | $ 701.30M | $ 811.90M | $ 977.80M |
| Net Income | $ 397.50M | $ 432.20M | $ 357.60M | $ 452.40M | $ 601.10M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 569.80M | $ 449.80M | $ 352.40M | $ 552.60M | $ 803.50M |
| Total Assets | $ 5.57B | $ 5.77B | $ 5.26B | $ 5.19B | $ 4.61B |
| Total Debt | $ 461.40M | $ 490.70M | $ 518.80M | $ 505.40M | $ 462.50M |
| Net Debt | $ -108.40M | $ 40.90M | $ 166.40M | $ -47.20M | $ -341.00M |
| Total Liabilities | $ 1.47B | $ 1.56B | $ 1.51B | $ 1.54B | $ 1.44B |
| Stockholders' Equity | $ 4.10B | $ 4.20B | $ 3.75B | $ 3.60B | $ 3.11B |
| Cash Flow | |||||
| Free Cash Flow | $ 453.00M | $ 321.50M | $ 107.10M | $ 188.40M | $ 534.60M |
| Operating Cash Flow | $ 788.30M | $ 667.30M | $ 445.40M | $ 475.10M | $ 824.70M |
| Investing Cash Flow | $ -461.70M | $ -359.80M | $ -488.80M | $ -528.10M | $ -307.30M |
| Financing Cash Flow | $ -155.40M | $ -212.60M | $ -122.30M | $ -244.20M | $ -140.60M |
Currency in EUR
